


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): ~~Use of an A~~ method of treating or preventing at least one disease selected from the group consisting of diabetes type II, obesity, and appetite regulation, in a subject in need thereof, comprising administering at least one aryl dicarboxamide of formula (I):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts ~~and pharmaceutically active derivatives thereof~~, wherein

A is an aminocarbonyl moiety of the formula  $-\text{CO}-\text{NHR}^6$ , wherein  $\text{R}^6$  is  $\text{C}_6\text{-C}_{15}$  alkyl,  $\text{C}_2\text{-C}_{15}\text{-alkenyl}$ ,  $\text{C}_2\text{-C}_{15}\text{-alkynyl}$ , ~~a 3-8-membered cycloalkyl,  $\text{C}_1\text{-C}_6$  alkyl-(3-8 membered)~~ cycloalkyl, phenyl,  $\text{C}_1\text{-C}_{12}$  alkyl phenyl,  $\text{C}_2\text{-C}_6\text{-alkenyl}$  phenyl, or  $\text{C}_2\text{-C}_6\text{-alkynyl}$  phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

$\text{R}^1$  and  $\text{R}^2$  are independently from each other ~~[[is]]~~ selected from the group consisting of hydrogen ~~[[or]]~~ and  $\text{C}_1\text{-C}_6\text{-alkyl}$ ;

$\text{R}^3$  is selected from the group consisting of  $\text{C}_1\text{-C}_6\text{-alkyl}$ ,  $\text{C}_2\text{-C}_6\text{-alkenyl}$ ,  $\text{C}_2\text{-C}_6\text{-alkynyl}$ ,  $\text{C}_1\text{-C}_6\text{-alkoxy}$ ,  $\text{C}_1\text{-C}_6\text{-alkyl amine}$ ,  $\text{C}_1\text{-C}_6\text{-alkyl alkoxy}$ , aryl, heteroaryl, saturated ~~or unsaturated~~ 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered


heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl cycloalkyl, and C<sub>2</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl;

R<sup>4</sup> and R<sup>5</sup> are each independently from each other selected from the group consisting of H, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, carboxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> alkyl carboxy, C<sub>2</sub>-C<sub>3</sub> alkenyl carboxy, C<sub>2</sub>-C<sub>3</sub> alkynyl carboxy, and amino, or R<sup>4</sup> and R<sup>5</sup> may form an unsaturated or saturated heterocyclic ring, whereby at least one of R<sup>4</sup> or R<sup>5</sup> is not a hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl;

~~for the preparation of a medicament for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS) to the subject in an amount sufficient to treat or prevent the at least one disease.~~

Claim 2 (Currently Amended): The method of claim 1, wherein the method is a method of treating ~~Use of an aryl dicarboxamide according to claim 1 a for the preparation of a medicament for the treatment and/or prevention of diabetes type II, obesity or for appetite regulation.~~

Claim 3 (Currently Amended): A method of treating or preventing at least one disease selected from the group consisting of diabetes, inadequate glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, and polycystic ovary syndrome, in a subject in need thereof, comprising, administering at least one aryl dicarboxamide of formula (I):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is an aminocarbonyl moiety of the formula  $-\text{CO-NHR}^6$ , wherein  $\text{R}^6$  is  $\text{C}_6\text{-C}_{15}$  alkyl,  $\text{C}_2\text{-C}_{15}$ -alkenyl,  $\text{C}_2\text{-C}_{15}$ -alkynyl, a 3-8 membered cycloalkyl,  $\text{C}_1\text{-C}_6$  alkyl-(3-8 membered) cycloalkyl, phenyl,  $\text{C}_1\text{-C}_{12}$  alkyl phenyl,  $\text{C}_2\text{-C}_6$ -alkenyl phenyl, or  $\text{C}_2\text{-C}_6$ -alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

$\text{R}^1$  and  $\text{R}^2$  are independently from each other selected from the group consisting of hydrogen and  $\text{C}_1\text{-C}_6$ -alkyl;

$\text{R}^3$  is selected from the group consisting of  $\text{C}_1\text{-C}_6$ -alkyl,  $\text{C}_2\text{-C}_6$ -alkenyl,  $\text{C}_2\text{-C}_6$ -alkynyl,  $\text{C}_1\text{-C}_6$ -alkoxy,  $\text{C}_1\text{-C}_6$ -alkyl amine,  $\text{C}_1\text{-C}_6$ -alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl,  $\text{C}_1\text{-C}_6$ -alkyl aryl,  $\text{C}_1\text{-C}_6$ -alkyl heteroaryl,  $\text{C}_2\text{-C}_6$ -alkenyl aryl,  $\text{C}_2\text{-C}_6$ -alkenyl heteroaryl,  $\text{C}_2\text{-C}_6$ -alkynyl aryl,  $\text{C}_2\text{-C}_6$ -alkynyl heteroaryl,  $\text{C}_1\text{-C}_6$ -alkyl cycloalkyl,  $\text{C}_1\text{-C}_6$ -alkyl heterocycloalkyl,  $\text{C}_2\text{-C}_6$ -alkenyl cycloalkyl,  $\text{C}_2\text{-C}_6$ -alkenyl heterocycloalkyl,  $\text{C}_2\text{-C}_6$ -alkynyl cycloalkyl, and  $\text{C}_2\text{-C}_6$ -alkynyl heterocycloalkyl;


$\text{R}^4$  and  $\text{R}^5$  are each independently from each other selected from the group consisting of H, hydroxy,  $\text{C}_1\text{-C}_6$  alkyl, carboxy,  $\text{C}_1\text{-C}_6$  alkoxy,  $\text{C}_1\text{-C}_3$  alkyl carboxy,  $\text{C}_2\text{-C}_3$  alkenyl

carboxy, C<sub>2</sub>-C<sub>3</sub> alkynyl carboxy, and amino, or R<sup>4</sup> and R<sup>5</sup> may form an unsaturated or saturated heterocyclic ring, whereby at least one of R<sup>4</sup> or R<sup>5</sup> is not a hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl, to the subject in an amount sufficient to treat or prevent the at least one disease Use of an aryl dicarboxamide according to claim 1 for the preparation of a pharmaceutical composition for the modulation of the activity of PTPs.

Claim 4 (Currently Amended): Use according to The method of claim 3, wherein the method is a method of treating wherein the PTP is PTP1B.

Claim 5 (Canceled).

Claim 6 (Currently Amended): A method of treating or preventing at least one metabolic disorder mediated by insulin resistance or hyperglycemia, in a subject in need thereof, comprising, administering at least one aryl dicarboxamide of formula (I):



as well as its geometrical isomers, its optically active forms as enantiomers, diastereomers and its racemate forms, as well as pharmaceutically acceptable salts thereof, wherein

A is an aminocarbonyl moiety of the formula -CO-NHR<sup>6</sup>, wherein R<sup>6</sup> is C<sub>6</sub>-C<sub>15</sub> alkyl, C<sub>2</sub>-C<sub>15</sub>-alkenyl, C<sub>2</sub>-C<sub>15</sub>-alkynyl, a 3-8 membered cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl-(3-8 membered) cycloalkyl, phenyl, C<sub>1</sub>-C<sub>12</sub> alkyl phenyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl phenyl, or C<sub>2</sub>-C<sub>6</sub>-alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

R<sup>1</sup> and R<sup>2</sup> are independently from each other selected from the group consisting of hydrogen and C<sub>1</sub>-C<sub>6</sub>-alkyl;

R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl amine, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl cycloalkyl, and C<sub>2</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl;

R<sup>4</sup> and R<sup>5</sup> are each independently from each other selected from the group consisting of H, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, carboxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> alkyl carboxy, C<sub>2</sub>-C<sub>3</sub> alkenyl carboxy, C<sub>2</sub>-C<sub>3</sub> alkynyl carboxy, and amino, or R<sup>4</sup> and R<sup>5</sup> may form an unsaturated or saturated heterocyclic ring, whereby at least one of R<sup>4</sup> or R<sup>5</sup> is not a hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl.

---

to the subject in an amount sufficient to treat or prevent the at least one disorder


~~Use according to claim 4 for the treatment or prevention of disorders mediated by~~  
**PTP1B.**

Claim 7 (Currently Amended): ~~Use according to any of claims 1 to 6~~ The method of claim 1, wherein R<sup>1</sup> and R<sup>2</sup> are each H.

Claim 8 (Currently Amended): ~~Use according to any of claims 1 to 7~~ The method of claim 1, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 9 (Currently Amended): ~~Use according to any of claims 1 to 8~~ The method of claim 1, wherein A is a moiety of the formula  $-\text{CO-NHR}^6$ , wherein  $\text{R}^6$  is  $\text{C}_6\text{-C}_{15}$  alkyl,  $\text{C}_2\text{-C}_{15}$ -alkenyl,  $\text{C}_2\text{-C}_{15}$ -alkynyl, a 3-8 membered cycloalkyl,  $\text{C}_1\text{-C}_6$  alkyl-(3-8 membered) cycloalkyl, phenyl,  $\text{C}_1\text{-C}_{12}$  alkyl phenyl,  $\text{C}_2\text{-C}_6$ -alkenyl phenyl, or  $\text{C}_2\text{-C}_6$ -alkynyl phenyl.

Claim 10 (Currently Amended): An aryl dicarboxamide according to any of the formulae (Ia), (Ib) or (Ic):



wherein

A is an aminocarbonyl moiety of the formula  $-\text{CO-NHR}^6$  wherein  $\text{R}^6$  is  $\text{C}_6\text{-C}_{15}$  alkyl,  $\text{C}_2\text{-C}_{15}$ -alkenyl,  $\text{C}_2\text{-C}_{15}$ -alkynyl, a 3-8 membered cycloalkyl,  $\text{C}_1\text{-C}_6$  alkyl-(3-8 membered) cycloalkyl, phenyl,  $\text{C}_1\text{-C}_{12}$  alkyl phenyl,  $\text{C}_2\text{-C}_6$ -alkenyl phenyl, or  $\text{C}_2\text{-C}_6$ -alkynyl phenyl;


Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

$R^1$  and  $R^2$  are independently from each other ~~[[is]]~~ selected from the group consisting of hydrogen ~~[[or]]~~ and  $C_1$ - $C_6$ -alkyl;

$R^3$  is selected from the group consisting of  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkoxy,  $C_1$ - $C_6$ -alkyl amine,  $C_1$ - $C_6$ -alkyl alkoxy, aryl, heteroaryl, saturated ~~or~~ ~~unsaturated~~ 3-8-membered cycloalkyl, unsaturated 3-8 membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety,  $C_1$ - $C_6$ -alkyl aryl,  $C_1$ - $C_6$ -alkyl heteroaryl,  $C_2$ - $C_6$ -alkenyl aryl,  $C_2$ - $C_6$ -alkenyl heteroaryl,  $C_2$ - $C_6$ -alkynyl aryl,  $C_2$ - $C_6$ -alkynyl heteroaryl,  $C_1$ - $C_6$ -alkyl cycloalkyl,  $C_1$ - $C_6$ -alkyl heterocycloalkyl,  $C_2$ - $C_6$ -alkenyl cycloalkyl,  $C_2$ - $C_6$ -alkenyl heterocycloalkyl,  $C_2$ - $C_6$ -alkynyl cycloalkyl, and  $C_2$ - $C_6$ -alkynyl heterocycloalkyl.

Claim 11 (Currently Amended): An aryl dicarboxamide according to formula (Ib) or (Ic):



wherein

A is an aminocarbonyl moiety of the formula  $-\text{CO}-\text{NHR}^6$  wherein  $R^6$  is  $C_6$ - $C_{15}$  alkyl,  $C_2$ - $C_{15}$ -alkenyl,  $C_2$ - $C_{15}$ -alkynyl, a 3-8 membered cycloalkyl,  $C_1$ - $C_6$  alkyl-(3-8 membered) cycloalkyl, phenyl,  $C_1$ - $C_{12}$  alkyl phenyl,  $C_2$ - $C_6$ -alkenyl phenyl, or a  $C_2$ - $C_6$ -alkynyl phenyl;

Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

n is either 0 or 1;

R<sup>1</sup> and R<sup>2</sup> are independently from each other is selected from the group consisting of hydrogen ~~[[or]]~~ and C<sub>1</sub>-C<sub>6</sub>-alkyl;

R<sup>3</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl amine, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, aryl, heteroaryl, saturated or ~~unsaturated~~ 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered heterocycloalkyl, an acyl moiety, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl cycloalkyl, and C<sub>2</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl.

Claim 12 (Currently Amended): ~~[[An]]~~ The aryl dicarboxamide according to claim 10 ~~or 11~~, wherein R<sup>1</sup> and R<sup>2</sup> are each H.

---

Claim 13 (Currently Amended): ~~[[An]]~~ The aryl dicarboxamide according to ~~any of claims 10 to 12~~ claim 10, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 14 (Currently Amended): ~~[[An]]~~ The aryl dicarboxamide according to claim 13, wherein R<sup>6</sup> is selected from the group consisting of C<sub>8</sub>-C<sub>12</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkyl phenyl which may be substituted by C<sub>1</sub>-C<sub>8</sub> alkyl, ~~[[or]]~~ and phenoxy.



Claim 15 (Currently Amended): An aryl dicarboxamide ~~according to any of the~~  
~~preceding claims~~ selected from the group consisting of :

5-[(3-cyclopentylpropanoyl)(4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)amino]-  
2-hydroxybenzoic acid

5-[(3-cyclopentylpropanoyl)(4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)amino]-  
2-hydroxybenzoic acid

[4-( { { [2-(4- {[ (4-pentylbenzyl)amino]carbonyl} phenyl)-1,3-thiazol-4-yl]methyl} -  
[(2E)-3-phenylprop-2-enoyl]amino } methyl)phenoxy]acetic acid

5-[(3-cyclopentylpropanoyl)(4- {[ (4-pentylbenzyl)amino]carbonyl} benzyl)amino]-2-  
hydroxybenzoic acid

2-hydroxy-5- { (4- {[ (4-pentylbenzyl)amino]carbonyl} benzyl) [4-(trifluoromethyl)-  
benzoyl]amino } benzoic acid

2-hydroxy-5- [ (4- {[ (4-phenoxybenzyl)amino]carbonyl} -1,3-thiazol-2-yl)methyl] (3-  
phenylpropanoyl)amino] benzoic acid

5- { benzoyl [ (4- {[ (4-phenoxybenzyl)amino]carbonyl} -1,3-thiazol-2-yl)methyl] -  
amino } -2-hydroxybenzoic acid

---

2-hydroxy-5- { [ (4- {[ (4-phenoxybenzyl)amino]carbonyl} -1,3-thiazol-2-yl)methyl] [4-  
(trifluoromethyl)benzoyl]amino } benzoic acid

5- [(cyclohexylcarbonyl) (4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)amino] -2-  
hydroxybenzoic acid

2-hydroxy-5- [ (4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl) (3-phenylpropanoyl) -  
amino] benzoic acid

5- [benzoyl (4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)amino] -2-hydroxybenzoic  
acid

5-[acetyl(4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)amino]-2-hydroxybenzoic acid

5-[(4-cyanobenzoyl)(4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)amino]-2-hydroxybenzoic acid

2-hydroxy-5-[(phenoxyacetyl)(4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)-amino]-benzoic acid

2-hydroxy-5-{(4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid

2-hydroxy-5-{(4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)[(2*E*)-3-phenylprop-2-enoyl]amino}benzoic acid

5-[(*N,N*-dimethylglycyl)(4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)amino]-2-hydroxybenzoic acid

2-hydroxy-5-[(3-methylbut-2-enoyl)(4- {[ (4-phenoxybenzyl)amino]carbonyl} benzyl)-amino]benzoic acid

2-hydroxy-5-{[4-[(octylamino)carbonyl]benzyl}(phenoxyacetyl)amino]methyl}-benzoic acid

---

2-hydroxy-5-({4-[(octylamino)carbonyl]benzyl}[4-(trifluoromethyl)benzoyl]-amino}methyl)benzoic acid

2-hydroxy-5-({4-[(octylamino)carbonyl]benzyl}[(2*E*)-3-phenylprop-2-enoyl]-amino}methyl)benzoic acid

5-{[(3-cyclopentylpropanoyl)(4- {[ (4-pentylbenzyl)amino]carbonyl} benzyl)-amino]methyl}-2-hydroxybenzoic acid

2-hydroxy-5-{[(4- {[ (4-pentylbenzyl)amino]carbonyl} benzyl)(phenoxyacetyl)-amino]methyl}benzoic acid

2-hydroxy-5-({(4-{{(4-pentylbenzyl)amino}carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}methyl)benzoic acid

2-hydroxy-5-{{(3-methylbut-2-enoyl)(4-{{(4-pentylbenzyl)amino}carbonyl}-benzyl)amino}methyl}benzoic acid

5-{{(3-cyclopentylpropanoyl)(4-{{(4-phenylbutyl)amino}carbonyl}benzyl)-amino}methyl}-2-hydroxybenzoic acid

2-hydroxy-5-({(4-{{(4-pentylbenzyl)amino}carbonyl}-1,3-thiazol-2-yl)methyl}[(2*E*)-3-phenylprop-2-enoyl]amino}methyl)benzoic acid

[4-({(4-{{(4-phenoxybenzyl)amino}carbonyl}benzyl)[4-(trifluoromethyl)benzoyl]-amino}methyl)phenoxy]acetic acid

2-hydroxy-5-[(4-{{(4-pentylbenzyl)amino}carbonyl}benzyl)(3-phenylpropanoyl)-amino]benzoic acid

4-[(3-cyclopentylpropanoyl)(4-{{(4-pentylbenzyl)amino}carbonyl}benzyl)amino]-2-hydroxybenzoic acid

2-hydroxy-4-{{(4-{{(4-pentylbenzyl)amino}carbonyl}benzyl)[4-(trifluoromethyl)-benzoyl]amino}benzoic acid

---

2-hydroxy-5-[[2-(4-{{(4-pentylbenzyl)amino}carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(phenoxyacetyl)amino]benzoic acid

2-hydroxy-5-{{[2-(4-{{(4-pentylbenzyl)amino}carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}benzoic acid

5-(((6-chloropyridin-3-yl)carbonyl){[2-(4-{{(4-pentylbenzyl)amino}carbonyl}-phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid

5-((4-cyanobenzoyl){[2-(4-{{(4-pentylbenzyl)amino}carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid

2-hydroxy-5-((3-methylbut-2-enoyl){[2-(4-{{(4-pentylbenzyl)amino]carbonyl}-phenyl)-1,3-thiazol-4-yl]methyl}amino)benzoic acid

5-((3-cyclopentylpropanoyl){[2-(4-{{(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid

2-hydroxy-5-{{[2-(4-{{(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}{4-(trifluoromethyl)benzoyl]amino}benzoic acid

2-hydroxy-5-[[2-(4-{{(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}{(3-phenylpropanoyl)amino]benzoic acid

5-(benzoyl{[2-(4-{{(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)-2-hydroxybenzoic acid

[4-({[2-(4-{{(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}{4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid

(4-{{[2-(4-{{(4-pentylbenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}{(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid

[4-({[2-(4-{{(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}{4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid

(4-{{[2-(4-{{(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}{(3-phenylpropanoyl)amino]methyl}phenoxy)acetic acid

[4-({[2-(4-{{(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}{(2E)-3-phenylprop-2-enoyl]amino}methyl)phenoxy]acetic acid

{4-(((N,N-dimethylglycyl){[2-(4-{{(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid

{4-(((cyclohexylcarbonyl){[2-(4-{{(4-phenylbutyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid

{4-[(phenoxyacetyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid

[4-({[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}[4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid

(4-{[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}(3-phenylpropanoyl)amino)methyl}phenoxy)acetic acid

{4-[(cyclohexylcarbonyl){[2-(4-{[(4-phenoxybenzyl)amino]carbonyl}phenyl)-1,3-thiazol-4-yl]methyl}amino)methyl]phenoxy}acetic acid

[4-({[2-(4-{[(octylamino)carbonyl]phenyl}-1,3-thiazol-4-yl)methyl][4-(trifluoromethyl)benzoyl]amino}methyl)phenoxy]acetic acid; and


(4-{[2-(4-{[(octylamino)carbonyl]phenyl}-1,3-thiazol-4-yl)methyl}(3-phenylpropanoyl)amino)methyl}phenoxy)acetic acid.

Claim 16 (Currently Amended): [[An]] A pharmaceutical composition comprising at least one aryl dicarboxamide according to claim 11 and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof ~~aryl dicarboxamide according to any of the claims 10 to 15 for use as a medicament.~~

Claim 17 (Currently Amended): A pharmaceutical composition ~~containing~~ comprising at least one aryl dicarboxamide according to ~~any of claims 10 to 15~~ claim 10 and a pharmaceutically acceptable carrier, diluent, ~~[[or]] excipient, or combination~~ thereof.

Claim 18 (Currently Amended): A method of preparing ~~[[an]]~~ the aryl dicarboxamide of formula (I) ~~according to any of claims 10 to 15~~, comprising the

~~de-protection and/or transformation step of~~ deprotecting, transforming, or deprotecting and transforming (I') to form the aryl dicarboxamide (Ia):



wherein  $\text{R}^1, \text{R}^2, \text{R}^3, \text{R}^4, \text{R}^5, \text{R}^{4'}, \text{R}^{5'}$ ,  $n$  and  $\text{Cy}$  are as above defined and  $\text{FG}$  is  $\text{A}$  or a leaving group,

wherein

$\text{A}$  is an aminocarbonyl moiety of the formula  $-\text{CO}-\text{NHR}^6$ , wherein  $\text{R}^6$  is  $\text{C}_6\text{-C}_{15}$  alkyl,  $\text{C}_2\text{-C}_{15}$ -alkenyl,  $\text{C}_2\text{-C}_{15}$ -alkynyl, a 3-8 membered cycloalkyl,  $\text{C}_1\text{-C}_6$  alkyl-(3-8 membered) cycloalkyl, phenyl,  $\text{C}_1\text{-C}_{12}$  alkyl phenyl,  $\text{C}_2\text{-C}_6$ -alkenyl phenyl, or  $\text{C}_2\text{-C}_6$ -alkynyl phenyl;

$\text{Cy}$  is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group;

$n$  is either 0 or 1;

$\text{R}^1$  and  $\text{R}^2$  are independently from each other is selected from the group consisting of hydrogen and  $\text{C}_1\text{-C}_6$ -alkyl;

$\text{R}^3$  is selected from the group consisting of  $\text{C}_1\text{-C}_6$ -alkyl,  $\text{C}_2\text{-C}_6$ -alkenyl,  $\text{C}_2\text{-C}_6$ -alkynyl,  $\text{C}_1\text{-C}_6$ -alkoxy,  $\text{C}_1\text{-C}_6$ -alkyl amine,  $\text{C}_1\text{-C}_6$ -alkyl alkoxy, aryl, heteroaryl, saturated 3-8-membered cycloalkyl, unsaturated 3-8-membered cycloalkyl, 3-8-membered

heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl heterocycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl cycloalkyl, and C<sub>2</sub>-C<sub>6</sub>-alkynyl heterocycloalkyl; and wherein

R<sup>4</sup> and R<sup>5</sup> are each independently from each other selected from the group consisting of H, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkyl, carboxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>3</sub> alkyl carboxy, C<sub>2</sub>-C<sub>3</sub> alkenyl carboxy, C<sub>2</sub>-C<sub>3</sub> alkynyl carboxy, and amino, or R<sup>4</sup> and R<sup>5</sup> may form an unsaturated or saturated heterocyclic ring, whereby at least one of R<sup>4</sup> or R<sup>5</sup> is not a hydrogen or C<sub>1</sub>-C<sub>6</sub> alkyl.

Claim 19 (New): The aryl dicarboxamide according to claim 11, wherein R<sup>1</sup> and R<sup>2</sup> are each H.

Claim 20 (New): The aryl dicarboxamide according to claim 11, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 21 (New): The aryl dicarboxamide according to claim 20, wherein R<sup>6</sup> is selected from the group consisting of C<sub>8</sub>-C<sub>12</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkyl phenyl which may be substituted by C<sub>1</sub>-C<sub>8</sub> alkyl, and phenoxy.

Claim 22 (New): The method of claim 3, wherein R<sup>1</sup> and R<sup>2</sup> are each H.

Claim 23 (New): The method of claim 6, wherein R<sup>1</sup> and R<sup>2</sup> are each H.

Claim 24 (New): The method of claim 3, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 25 (New): The method of claim 6, wherein Cy is selected from the group consisting of phenyl, thiazolyl, phenyl-thiazolyl, and thiazolyl-phenyl.

Claim 26 (New): The method of claim 3, wherein A is a moiety of the formula –CO-NHR<sup>6</sup>, wherein R<sup>6</sup> is C<sub>6</sub>-C<sub>15</sub> alkyl, C<sub>2</sub>-C<sub>15</sub>-alkenyl, C<sub>2</sub>-C<sub>15</sub>-alkynyl, a 3-8 membered cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl-(3-8 membered) cycloalkyl, phenyl, C<sub>1</sub>-C<sub>12</sub> alkyl phenyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl phenyl, or C<sub>2</sub>-C<sub>6</sub>-alkynyl phenyl.

Claim 27 (New): The method of claim 6, wherein A is a moiety of the formula –CO-NHR<sup>6</sup>, wherein R<sup>6</sup> is C<sub>6</sub>-C<sub>15</sub> alkyl, C<sub>2</sub>-C<sub>15</sub>-alkenyl, C<sub>2</sub>-C<sub>15</sub>-alkynyl, a 3-8 membered cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl-(3-8 membered) cycloalkyl, phenyl, C<sub>1</sub>-C<sub>12</sub> alkyl phenyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl phenyl, or C<sub>2</sub>-C<sub>6</sub>-alkynyl phenyl.

---

Claim 28 (New): The method of claim 6, wherein the method is a method of treating.